title: Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015.
abstract: Recent reports suggest that acute intoxications by synthetic cannabinoids are increasing in the United States (1,2). Synthetic cannabinoids, which were research compounds in the 1980s, are now produced overseas; the first shipment recognized to contain synthetic cannabinoids was seized at a U.S. border in 2008 (3). Fifteen synthetic cannabinoids are Schedule I controlled substances (3), but enforcement is hampered by the continual introduction of new chemical compounds (1,3). Studies of synthetic cannabinoids indicate higher cannabinoid receptor binding affinities, effects two to 100 times more potent than Δ(9)-tetrahydrocannabinol (the principal psychoactive constituent of cannabis), noncannabinoid receptor binding, and genotoxicity (4,5). Acute synthetic cannabinoid exposure reportedly causes a range of mild to severe neuropsychiatric, cardiovascular, renal, and other effects (4,6,7); chronic use might lead to psychosis (6,8). During 2010-2015, physicians in the Toxicology Investigators Consortium (ToxIC) treated 456 patients for synthetic cannabinoid intoxications; 277 of the 456 patients reported synthetic cannabinoids as the sole toxicologic agent. Among these 277 patients, the most common clinical signs of intoxication were neurologic (agitation, central nervous system depression/coma, and delirium/toxic psychosis). Relative to all cases logged by 50 different sites in the ToxIC Case Registry, there was a statistically significant association between reporting year and the annual proportion of synthetic cannabinoid cases. In 2015, reported cases of synthetic cannabinoid intoxication increased at several ToxIC sites, corroborating reported upward trends in the numbers of such cases (1,2) and underscoring the need for prevention.
authors.forename: Anne M
authors.initials: AM
authors.lastname: Riederer
authors.forename: Sharan L
authors.initials: SL
authors.lastname: Campleman
authors.forename: Robert G
authors.initials: RG
authors.lastname: Carlson
authors.forename: Edward W
authors.initials: EW
authors.lastname: Boyer
authors.forename: Alex F
authors.initials: AF
authors.lastname: Manini
authors.forename: Paul M
authors.initials: PM
authors.lastname: Wax
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Brent
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002186:Cannabinoids / Q000506:poisoning*; D002648:Child; D002675:Child, Preschool; D015198:Designer Drugs / Q000506:poisoning*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012042:Registries; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D002186:Cannabinoids; D015198:Designer Drugs